The Pep Edit Newsletter

Cheat sheet

Status: Investigational Reviewed

Larazotide

One of the few names people ask us about that actually has multiple human trials, mostly around celiac disease and intestinal permeability.

The evidence rail

How to read this
  1. Mechanistic: reached
  2. Cell research: reached
  3. Animal research: reached
  4. Human observational: reached
  5. Human clinical trial: reached
  6. Established clinical use: not reached
Evidence
Human clinical trialsRung 5 of 6. A designed trial in people with a comparison group. The bar for a real claim.
Status
InvestigationalBeing studied in registered human trials. Not approved.

What has it been studied for?

  • Tight junctions and gluten-related gut injury in human trials
  • Celiac-adjacent questions, not a general “gut peptide” slogan

What we know

  • Human trial data exists. That is rarer than the feed makes it sound
  • Its largest trial, a Phase 3 in celiac disease, was stopped early in 2022 after an interim analysis found it unlikely to succeed. That is a human result too

What we don’t

  • Whether the earlier, smaller trial results generalize to every gut complaint people map onto it online

Bottom line

This is a map of the evidence, not a recommendation.

Education only. Not medical advice. Not a protocol.

Keep reading

  • KPV

    A fragment of alpha-MSH studied for inflammation and skin. Small human data.

    Evidence: Small human studies. Reached rung 4 of 6, Human observational.Not FDA-approved
    InflammationGut healthSkin + hair
    Inflammation

  • BPC-157

    Widely discussed for gut and recovery. The animal literature is large. Human clinical evidence is still thin.

    Evidence: Limited human data. Reached rung 4 of 6, Human observational, with limited data.Not FDA-approved
    Gut healthRecoveryInflammation
    Gut / Recovery

New sheets, the day they publish.

One email a week. The study type named, every time.